- Home
- CGO vs ALGS Comparison
CGO vs ALGS Comparison
Compare CGO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- ALGS
- Stock Information
- Founded
- CGO 2004
- ALGS 2018
- Country
- CGO United States
- ALGS United States
- Employees
- CGO N/A
- ALGS 70
- Industry
- CGO Investment Managers
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- CGO Finance
- ALGS Health Care
- Exchange
- CGO Nasdaq
- ALGS Nasdaq
- Market Cap
- CGO 113.2M
- ALGS 38.8M
- IPO Year
- CGO N/A
- ALGS 2020
- Fundamental
- Price
- CGO $10.39
- ALGS $10.04
- Analyst Decision
- CGO
- ALGS Strong Buy
- Analyst Count
- CGO 0
- ALGS 1
- Target Price
- CGO N/A
- ALGS $70.00
- AVG Volume (30 Days)
- CGO 34.7K
- ALGS 238.4K
- Earning Date
- CGO 01-01-0001
- ALGS 03-10-2025
- Dividend Yield
- CGO 9.25%
- ALGS N/A
- EPS Growth
- CGO N/A
- ALGS N/A
- EPS
- CGO N/A
- ALGS N/A
- Revenue
- CGO N/A
- ALGS $3,945,000.00
- Revenue This Year
- CGO N/A
- ALGS N/A
- Revenue Next Year
- CGO N/A
- ALGS N/A
- P/E Ratio
- CGO N/A
- ALGS N/A
- Revenue Growth
- CGO N/A
- ALGS N/A
- 52 Week Low
- CGO $7.90
- ALGS $6.76
- 52 Week High
- CGO $10.93
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- CGO 24.99
- ALGS 23.70
- Support Level
- CGO $10.37
- ALGS $9.51
- Resistance Level
- CGO $11.71
- ALGS $11.17
- Average True Range (ATR)
- CGO 0.20
- ALGS 1.59
- MACD
- CGO -0.08
- ALGS -0.24
- Stochastic Oscillator
- CGO 9.52
- ALGS 13.50
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in global equities, convertible securities, and high-yield corporate bonds.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.